Section Arrow
Quote
KLRA.NASDAQ
- Kailera Therapeutics Inc
Quotes are at least 15-min delayed:2026/06/04 20:34 EDT
Regular Hours
Last
 20.99
-1.39 (-6.21%)
Day High 
22.925 
Prev. Close
22.38 
1-M High
25.7 
Volume 
489.77K 
Bid
20.95
Ask
23.8
Day Low
20.97 
Open
22.28 
1-M Low
19.01 
Market Cap 
2.90B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 21.98 
20-SMA 21.83 
50-SMA -- 
52-W High 28.2271 
52-W Low 19.01 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.78/--
Enterprise Value
2.91B
Balance Sheet
Book Value Per Share
-3.33
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
VERUVeru Inc4.23+1.98+88.00%-- 
AIMAIM ImmunoTech Inc.0.5913-0.1407-19.22%-- 
INDPIndaptus Therapeutics Inc4.75+2.54+114.93%-- 
RXRXRecursion Pharmaceuticals3.8+0.33+9.51%-- 
ADTXAditxt Inc.0.077-0.0179-18.86%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.